Jean‐Louis Chiasson

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al. · The Lancet · 2002 · 2.5K citations

Medicine, Pharmacotherapy, Preventive Medicine +14

Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance

Jean‐Louis Chiasson, Robert G. Josse, Ramón Gomis et al. · JAMA · 2003 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +17

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein

Thomas M.S. Wolever, Alison L. Gibbs, Christine C. Mehling et al. · American Journal of Clinical Nutrition · 2008 · 335 citations · Full text

Agriculture, Nutrition, Nutritional Sciences +17